Replication and single-cycle delivery of SARS-CoV-2 replicons.

Autor: Ricardo-Lax I; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Luna JM; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Thao TTN; Institute of Virology and Immunology (IVI), Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.; Graduate School for Biomedical Science, University of Bern, Bern, Switzerland., Le Pen J; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Yu Y; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Hoffmann HH; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Schneider WM; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Razooky BS; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Fernandez-Martinez J; Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY 10065, USA., Schmidt F; Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA., Weisblum Y; Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA., Trüeb BS; Institute of Virology and Immunology (IVI), Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Berenguer Veiga I; Institute of Virology and Immunology (IVI), Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Schmied K; Institute of Virology and Immunology (IVI), Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Ebert N; Institute of Virology and Immunology (IVI), Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Michailidis E; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Peace A; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Sánchez-Rivera FJ; Cancer Biology and Genetics, MSKCC, New York, NY 10065, USA., Lowe SW; Cancer Biology and Genetics, MSKCC, New York, NY 10065, USA., Rout MP; Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY 10065, USA., Hatziioannou T; Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA., Bieniasz PD; Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA., Poirier JT; Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, NY 10016, USA., MacDonald MR; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA., Thiel V; Institute of Virology and Immunology (IVI), Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Rice CM; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Jazyk: angličtina
Zdroj: Science (New York, N.Y.) [Science] 2021 Nov 26; Vol. 374 (6571), pp. 1099-1106. Date of Electronic Publication: 2021 Oct 14.
DOI: 10.1126/science.abj8430
Abstrakt: Molecular virology tools are critical for basic studies of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and for developing new therapeutics. Experimental systems that do not rely on viruses capable of spread are needed for potential use in lower-containment settings. In this work, we use a yeast-based reverse genetics system to develop spike-deleted SARS-CoV-2 self-replicating RNAs. These noninfectious self-replicating RNAs, or replicons, can be trans-complemented with viral glycoproteins to generate replicon delivery particles for single-cycle delivery into a range of cell types. This SARS-CoV-2 replicon system represents a convenient and versatile platform for antiviral drug screening, neutralization assays, host factor validation, and viral variant characterization.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje